21% sales growth for Boston Scientific:
This article was originally published in Clinica
Boston Scientific's total sales rose 21% to $1.9 billion in the year ended December 31. Excluding exchange rate effects, this represents an increase of 26%. In the fourth quarter, sales were $493 million, a 14% increase, or 19% excluding exchange rate effects. The US company will announce its full annual results in February.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.